Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 studyGiuseppe Saglio, Hervé Dombret, Ricardo Pasqüini et al.|Cancer|2010Cited by 125
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 studyMichael B. Lilly, Giovanni Martinelli, Oliver G. Ottmann et al.|American Journal of Hematology|2009Cited by 98